Lactobacillus helveticus R0052 and Bifidobacterium longum R0175: The Psychobiotic Combination

← Back to articles

The probiotic combination of Lactobacillus helveticus R0052 plus Bifidobacterium longum R0175 — sold under the brand names Cerebiome and Probio'Stick by Lallemand Health Solutions — is the single most-tested "psychobiotic" formulation in the literature. The term itself, coined by Dinan and Cryan in 2013, refers to live organisms that confer a mental-health benefit when administered in adequate amounts. The R0052/R0175 combination is the one with the most rigorous human RCT evidence for mood and stress endpoints, even if effect sizes remain modest and inconsistent.

The Original Messaoudi 2011 Trial

The breakthrough paper was Messaoudi et al. 2011 in the British Journal of Nutrition: 55 healthy adults randomized to 30 days of L. helveticus R0052 + B. longum R0175 at a combined 3 × 10⁹ CFU daily versus placebo. The probiotic arm showed significant reductions in Hopkins Symptom Checklist global severity, Hospital Anxiety and Depression Scale, and 24-hour urinary free cortisol. The trial was small but well-controlled, and it set off a wave of follow-up research. A French validation in adults with mild-to-moderate self-reported stress replicated several of the findings.

Follow-Up Trials: Mixed but Net Positive

Subsequent RCTs of the Lactobacillus helveticus + B. longum combination have produced a mixed but tilted-positive evidence base. A 2017 RCT in 79 medical students under exam stress showed reductions in salivary cortisol and self-reported stress. A 2019 RCT in adults with diagnosed major depressive disorder failed to outperform placebo on the primary depression endpoint but showed signals on stool serotonin metabolite levels — interpreted as a target-engagement positive without clinical translation. A 2022 meta-analysis pooling 7 RCTs of this combination found a modest reduction in depression scores versus placebo, with effect size smaller than first-line antidepressants but with substantially better tolerability.

Mechanism: Vagal Signaling and HPA Axis

The proposed mechanism for L. helveticus R0052 and B. longum R0175 involves three convergent pathways: (1) reduction of intestinal inflammation and gut permeability, which lowers systemic inflammatory cytokines that act on CNS microglia; (2) vagal afferent stimulation via short-chain fatty acid production; and (3) modulation of the HPA axis, plausibly via gut-derived GABA and serotonin precursors. Vagotomized animal models lose the behavioral effect, supporting the vagal pathway. The mechanism remains incomplete but is one of the better-characterized in the psychobiotic space. See our gut-brain connection piece.

Dose, Form, and Practical Use

The trial-effective dose is a combined 3 × 10⁹ CFU per day of L. helveticus R0052 + B. longum R0175, taken as a single sachet or capsule with or without food. Continuation for at least 30 days before judging effect — the strongest signals emerged at the 30-day mark in most trials. The combination is not a substitute for SSRIs, CBT, or other first-line therapy in moderate-to-severe depression; it sits as an adjunct or as a low-cost trial in mild stress or subclinical mood symptoms. See the depression and anxiety condition pages.

Bottom Line

L. helveticus R0052 and B. longum R0175 is the most-studied probiotic combination for stress and mood, with modest but real reductions in HPA-axis activation and self-reported stress versus placebo. The effect sizes are small enough that the combination should be treated as an adjunct, not a primary therapy. It is one of the few probiotic indications where the strain-level brand evidence (Cerebiome / Probio'Stick) genuinely tracks the clinical data.